Minus und Minus iss immer BLUS

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.06.15    0,9401    0,9401§0,94 0,94 $ 2.950 2.773

GrB  

Branche Pharmazie
 

www.bellushealth.com ,GrB
 

Aktienanzahl 47,4 Mio. (Stand: 19.06.14)
 

Buch
http://www.ariva.de/bellus_health-aktie/times_and_sales?boerse_id=83 GrB  

Zeit       Kurs Stück
  16:17:25§0,898 $ 267
___________________
GRATULATION  

Zeit     Kurs Stück
  19:18:49§0,8861 $ 1.000
  19:04:26§0,8861 $ 500
___________________
GRATULATION          §
 

Zeit         Kurs Stück
  20:28:38§0,8624 $ 1.000
  19:06:47§0,886 $ 1.700
_____________________
GRATULATION  

http://www.bellushealth.com/English/investors/...rmation/default.aspx GrB  

http://www.bellushealth.com/files/doc_downloads/...et-Winter-2015.pdf GrB  

http://www.bellushealth.com/English/investors/...tations/default.aspx GrB  

BELLUS Health narrows timelines for the Phase III study for KIACTA™ and reports financial and operating results for the second quarter ended June 30, 2015 - See more at: http://www.bellushealth.com/English/investors/...sthash.MstvgETk.dpuf http://www.bellushealth.com/English/investors/...verview/default.aspx  

http://www.bellushealth.com/English/news/news-releases/default.aspx GrB  

 

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys.
The lead program KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. The Phase III Confirmatory Study completed its enrollment in January 2015 and is expected to conclude in 2016.
KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. A Phase II trial is expected to begin in the second half of 2015.
In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for treatment of sHUS are currently underway.
BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
- See more at: http://www.bellushealth.com/English/about-bellus/...ash.Ky3FxYUt.dpuf http://www.bellushealth.com/English/about-bellus/...file/default.aspx  

Frankfurt gucken ..Frankfurt ..und immer gucken mit die Augen und nich mit die Arsch ..look höör:::: 0,591 € +1,37% +0,008 € ,GrB

buran  

Zeit     Kurs Stück
  16:33:52§0,697 € 250
__________________
GRATULATION
 

Buch bitte selbst einsehen ..und danke ..und TOP

buran  

Datum Erster Hoch Tief Schluss Stücke Volumen
  16.06.16     1,813     1,813§1,715 1,74 $ 4.100 7.178

GrB  

Zeit      Kurs Stück
  08:11:09§0,211 € 3.000
________________
GRATULATION
 

welche Tabletten du nimmst, damit ich dir viell. schwächere verschreiben kann, die nicht so viele sichtbare Nebenwirkungen haben ...  

Amibuch http://www.ariva.de/bellus_health-aktie/times_and_sales?boerse_id=83 GrB  

suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. http://www.ariva.de/news/iiroc-trade-resumption-blu-6054887

 

Bellus steigt in den Himmel und keiner merkt es?

Gruß vom
Advamillionär  

...und (fast) keiner interessiert sich für diese  Aktie...

Gruß vom
Advamillionär